Typhoid fever cases in the U.S. military.

BACKGROUND: Salmonella enterica, serovar Typhi (S. Typhi), a causative agent of enteric fever (typhoid fever), predominately affects populations in developing regions with poor access to clean food and water. In addition, travelers to these regions are at risk of exposure. METHODS: We report the epidemiological characteristics of S. Typhi cases among active duty United States military personnel from 1998 to 2011 using data obtained from the Defense Medical Surveillance System. Cases were identified based on International Classification for Disease Ninth Edition - Clinical Modification codes. RESULTS: We identified a total of 205 cases S. Typhi for an incidence of 1.09 per 100,000 person-years. Cases were on average 31.7 years old, predominately married (n = 129, 62.9 %), Caucasian (n = 142, 69.3 %), male (n = 176, 85.9 %), and had a high school education (n = 101, 49.3 %). Of the identified cases, 122 had received a Typhoid vaccination within 4 years of diagnosis. CONCLUSION: This study provides an overview of enteric fever in the United States military. The incidence was similar to the general U.S. population except for increased incidence from 1998 to 2000, perhaps attributable to operational deployments in that period. Given that vaccination is an effective primary prevention measure against typhoid fever, active monitoring of pre-deployment vaccine history is warranted.

Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis.

OBJECTIVES: The objective of this systematic review and meta-analysis was to estimate the risk of developing functional dyspepsia (FD) following acute infectious gastroenteritis (IGE). METHODS: Eligible studies were identified through PubMed and EMBASE searches. Data and quality indicators were extracted by two authors from nine studies examining the risk of FD following IGE in 5,755 exposed individuals. RESULTS: Estimates of FD risk following IGE based on a random effects model yielded a pooled odds ratio (OR) of 2.18 (95% confidence interval (CI): 1.70-2.81). Subanalyses revealed differences in the odds of FD following self-reported IGE (OR: 2.83, 95% CI: 2.10-3.81) compared with documented IGE medical encounters (OR: 1.81, 95% CI: 1.26-2.58), and a decreasing FD risk with time from IGE (≤12 months: OR: 4.76, 95% CI: 2.47-9.20 and >12 months: OR: 1.97, 95% CI: 1.51-2.56). CONCLUSIONS: Taken together, these data suggest that the risk of developing FD is significantly increased following IGE.

Vaccination of active component US military personnel against Salmonella Typhi.

INTRODUCTION: Vaccination against Salmonella Typhi is one of the leading public health interventions reducing the risk of typhoid fever. There are two available licensed vaccines, Vivotif, oral live-attenuated, and Typhim Vi, intramuscular Vi capsular polysaccharide. The US military is a high risk travel population commonly vaccinated for S. Typhi. We describe the use of S. Typhi vaccination in this population and the acute reactogenicity profile of these vaccines. METHODS: Data were obtained from the Defense Medical Surveillance System and vaccination identified between 1998 and 2011 from vaccination codes. Clinical outcomes were assessed for four weeks post vaccination. Adverse event rates and odds ratios were estimated across the two vaccine types. RESULTS: A total of 1.9million predominately male military personnel received 3.6 million S. Typhi vaccinations with 94.3% of vaccinees receiving the Vi capsule vaccine though variability in the vaccine administered was observed. Receipt of other vaccinations in the 6months surrounding the S. Typhi vaccine was common. Rates of nausea (195 per 100,000 vaccinations), headache (13 per 100,000 vaccinations) and fever (40 per 100,000 vaccinations) were significantly higher following Vi capsule vaccination compared to receipt of Vivotif (130, 2, 10 per 100,000 vaccinations, respectively). In contrast the rates of rash and non-infectious diarrhea (186 and 426 per 100,000 vaccinations, respectively) were increased in those receiving Vivotif compared to the Vi capsule vaccine. DISCUSSION: The US military is a major consumer of S. Typhi vaccines. The parenterally administered vaccine appears to be more amenable, though we were limited in our ability to assess the reasons for its higher usage. While we observed a higher rate of several adverse events in subjects receiving the intramuscular vaccination, the overall rate of these events was low. Future studies assessing more long-term health outcomes are warranted.